SLC5A2 and type 2 diabetes mellitus: Furthermore, the combined therapy of SGLT2 inhibitors and GLP-1RAs has been confirmed to reduce the risk of major adverse cardiac and cerebrovascular events, as well as heart failure in patients with type 2 diabetes [172].